IMR Press / FBL / Volume 24 / Issue 6 / DOI: 10.2741/4772

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients
Show Less
1 Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China
2 Department of Neurosurgery, Children’s Hospital of Shanxi Province, Taiyuan, China
3 Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China
*Correspondence: (Zhi-Xiong Lin)
Front. Biosci. (Landmark Ed) 2019, 24(6), 1158–1166;
Published: 1 June 2019
(This article belongs to the Special Issue Leader sequences of coronavirus are altered during infection)

Experimental evidence has shown that chimeric switch receptor T (CSR-T) cells, activated by binding programmed death-ligand 1 on the tumor cell surface, lead to tumor regression in experimental animals. In this phase I clinical study, we evaluated the safety and bioactivity of CSR-T cell therapy in 14 patients with recurrent glioblastoma who were unresponsive to surgical resection and standard radiotherapy. Patients who received 108 CSR-T cells either intravenously or intracranially showed an increase in the levels of IFN-gamma and IL-6, respectively, in peripheral blood or cerbrospinal fluid (CSF). Moreover, the number of T cells present in CSF significantly increased after the treatment. Patients did not show grade 3 or 4 adverse effects. The evidence of in vivo biological activity and lack of adverse effects of treatment with CSR-T cells suggest that such treatment can be subjected to further analysis to show the efficacy of this new treatment strategy in the treatment of cancers that are not responsive to traditional therapeutic regimens.

Intravenous infusions
Figure 1.
Back to top